By Ellen Scharaga
Cancer drugs are a booming business, and pharmaceutical companies (such as Pfizer, the world’s largest pharmaceutical company) are willing to devote impressive resources to developing new drugs. This surge in interest in cancer drugs is due in part to new research discoveries, but it is also driven by the high cost that cancer drugs can command. Patients who are desperate for a new treatment will pay high sums to get it, and insurance companies don’t want to be seen as denying a dying person’s last hope. The company where I work, OncoMed Pharmaceutical Services, helps deliver cancer drugs and care-management services to patients. We also work with drug manufacturers, allowing us to streamline distribution while reducing the out-of-pocket cost to the patient. Although there is a lot of money to be made on new cancer drugs, OncoMed is devoted to helping patients receive these costly drugs at a fair price.
0 Comments
Leave a Reply. |